In patients at high bleeding risk (HBR), 3-month dual antiplatelet therapy (DAPT) is superior to 1-month DAPT with similar bleeding risk, and 3-month DAPT is noninferior to 12-month DAPT, and had significantly lower bleeding risk, in patients with low bleeding risk (LBR), a new study shows.